GUILFORD, Conn., March 17, 2022 — Invea Therapeutics, Inc., a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development by identifying and accelerating transformative therapies for inflammatory gastrointestinal and hepatobiliary disorders with unmet medical needs, announced today that an abstract entitled, “Using An Artificial Intelligence and Machine Learning Platform to Identify Mast Cell-Focused Therapeutic Targets for Gut-Brain Axis Disorders,” has been accepted for a poster presentation at the Keystone Symposia Gut-Brain Axis, and a second abstract entitled, “AI-Based Deconvolution of the Gut-Brain Axis and its Therapeutic Implications,” has been accepted for a poster presentation at Digestive Disease Week (DDW 2022). Invea Therapeutics is currently advancing programs for inflammatory Gastrointestinal (GI) and hepatobiliary disorders, including ulcerative colitis, eosinophilic esophagitis, eosinophilic gastroenteritis/duodenitis, and primary sclerosing cholangitis. The research that will be presented by Dr. Miles DeAngelis at Keystone Symposia Gut-Brain Axis and DDW2022 demonstrates the advantage of using AI and ML to deconvolute the bidirectional communication network of physical, cellular, and biochemical connections between the central nervous system, enteric nervous system, immune system, and GI tract, known as the Gut-Brain Axis (GBA). Dysregulation of the GBA is known to cause several functional and inflammatory GI and hepatobiliary conditions with neuropsychiatric manifestations. The company’s research has demonstrated the ability to use AI powered technology to better understand complex biological systems and prioritize targets and drugs that will have the greatest impact on disorders with significant unmet medical needs. Details of the time and location of the poster presentations are as follows: